Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Adaptive design for clinical trials

AACR 2010

17 - 21 Apr 2010

Published: 25 May 2010

Views: 9641

Rating:

Save

Dr Donald Berry - M.D. Anderson Cancer Center, University of Texas, USA

Dr Berry, speaking from AACR 2010, talks about adaptive deisgn for clinical trials. This includes identifying which patient populations benefit most, indentifying which drugs are most effective and the doses to be used in future trials. He also discusses the drugs investigated for target therapies, specifically for breast cancer treatment.

Categories:
Breast

Related Videos

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Exercise positively effects symptom burden and quality of life of metastatic...

Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands

Exercise positively effects symptom burden and quality of life of metastatic breast cancer patients ( Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

Implementation of the Choosing Wisely Africa List in 3 Countries

Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania

Implementation of the Choosing Wisely Africa List in 3 Countries ( Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

T-DM1 shows promise in treating unresectable locally advanced or metastatic...

Dr Sara Hurvitz - University of Washington, Seattle, USA

T-DM1 shows promise in treating unresectable locally advanced or metastatic HER2-positive breast cancer ( Dr Sara Hurvitz - University of Washington, Seattle, USA )

ASCO and its Sub-Saharan African outreach programme

Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology...

ASCO and its Sub-Saharan African outreach programme ( Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology (ASCO), USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

More from ecancer